GLP1R and type 2 diabetes mellitus: In this retrospective cohort study of 94 610 individuals with T2D and/or HF from 2014 to 2020, we observed that individuals with a lower medication co-payment had significantly higher odds of 12-month adherence to GLP1-RA and SGLT2i therapies compared with those with a higher co-payment.